Table 1.
Main Ongoing Clinical Trials of Antiangiogenics Agents Combined with ICIs
| Clinical Trial | Cancer Type | Treatment Line | Antiangiogenic Agent | Immunotherapy | Phase |
|---|---|---|---|---|---|
| NCT03377023 | NSCLC | ≥1 | Nintedanib | Nivolumab + Ipilimumab | I/II |
| NCT03896074 (BEAT) | NSCLC | 1 | Bevacizumab | Atezolizumab Compared to: Atezolizumab | II |
| NCT03689855 (RamAtezo-1) | NSCLC | ≥2 | Ramucirumab | Atezolizumab | II |
| NCT03786692 | EGFR+ NSCLC | >2 | Bevacizumab | Atezolizumab + chemotherapy Compared to: Bevacizumab + chemotherapy | II |
| NCT03713944 | Non-squamous NSCLC | 1 | Bevacizumab | Atezolizumab + chemotherapy | II |
| NCT03527108 | NSCLC | ≥2 | Ramucirumab | Nivolumab | II |
| NCT02954991 | NSCLC | ≥2 | Sitravatinib | Nivolumab | II |
| NCT03976375 (LEAP-008) | NSCLC | ≥2 | Lenvatinib | Pembrolizumab Compared to: Docetaxel Compared to: Lenvatinib monotherapy | III |
| NCT03829319 (LEAP-006) | Non-squamous NSCLC | 1 | Lenvatinib | Pembrolizumab + chemotherapy Compared to: Pembrolizumab + chemotherapy + placebo | III |
| WJOG11218L APPLE study | NSCLC | 1 | Bevacizumab | Atezolizumab + chemotherapy Compared to: Atezolizumab + chemotherapy | III |
Abbreviation: NSCLC, non-small cell lung cancer.